What happened?
On 13 August 2026 the FDA granted accelerated approval to iberdomide with daratumumab/hyaluronidase and dexamethasone for adults with multiple myeloma after at least one prior line containing a proteasome inhibitor and an immunomodulatory drug.
Why does it matter?
Multiple myeloma almost invariably becomes treatment-resistant over time. A new active regimen using a next-generation cereblon-modulating agent expands options after prior therapy and represents another step in increasingly deep response-driven myeloma treatment.
How to interpret the evidence
Accelerated approval is not the same as definitive proof of longer survival. The approval pathway uses an endpoint judged reasonably likely to predict clinical benefit, so confirmatory evidence and longer follow-up remain important.
What remains uncertain?
This does not mean multiple myeloma is cured or that the regimen is suitable for every patient after one prior treatment.
Medical News provides general health education. Individual treatment decisions depend on your circumstances and the advice of your clinical team.